David Irwin - Concepedia

Author

David Irwin

Alta Bates Summit Medical Center

Also Known As

D H Irwin, D Irwin, D. H. Irwin, D. Irwin, D.H. IRWIN, D.H. Irwin, David H Irwin, David H. Irwin, David Irwin

Publications

11.4K

Citations

H-Index

Concepts

All Affiliations

Alta Bates Summit Medical Center Dana-Farber Cancer Institute Millennium Engineering and Integration (United States)Moffitt Cancer Center Saint Vincent Health System

About

David Irwin is an author at Alta Bates Summit Medical Center specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.9K
2	Health Sciences	11	11	767
3	Immunology	6	6	341
4	Nephrology	1	1	183
5	Obstetrics	1	1	36

David Irwin

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, Bart Barlogie, James R. Berenson, New England Journal of Medicine	2003	2.6K
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, New England Journal of Medicine	2005	2.5K
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Sundar Jagannath, Bart Barlogie, James R. Berenson, British Journal of Haematology	2004	739
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib Paul G. Richardson, Hannah Briemberg, Sundar Jagannath, Journal of Clinical Oncology	2006	644
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Paul G. Richardson, Pieter Sonneveld, Michael Schuster, Blood	2007	509
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, British Journal of Haematology	2005	399
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Sundar Jagannath, Paul G. Richardson, Pieter Sonneveld, Leukemia Hematological MalignancyCytogeneticsMedicineGeneticsGenetic Disorder	2006	265
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer Edith A. Perez, Charles L. Vogel, David Irwin, Journal of Clinical Oncology	2001	248
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Anderley Gordon, N. Finkler, Robert P. Edwards, International Journal of Gynecological Cancer	2005	221
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, Annals of Oncology Venous DiseaseOncologyVenous ThrombosisCentral Venous CathetersPatient Safety	2005	219

Page 1